Clinical Trial Detail

NCT ID NCT00950365
Title Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Montefiore Medical Center, Eli Lilly and Company, OSI Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + Pemetrexed Disodium

Pemetrexed Disodium

Age Groups: adult

No variant requirements are available.